Terns Pharmaceuticals Inc (TERN)

$52.65 -0.04 (-0.08%)
Market Cap 6.08B
Revenue (ttm) 0.00
Net Income (ttm) -96.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 6,389,300
Avg Vol 6,265,948
Day's Range N/A - N/A
Shares Out 115.41M
Stochastic %K 68%
Beta -0.37
Analysts Sell
Price Target $53.62

Company Profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 525 5535
Fax: 650 275 4254
Address:
1065 East Hillsdale Boulevard, Suite 100, Foster City, United States
DragonAlgo
DragonAlgo Apr. 18 at 12:35 AM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-05-15 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $2.78 Stop: $2.00 TP1: $3.61 TP2: $4.72 TP3: $6.66 Rules-based execution profile. 🔗 https://dragonalgo.com
0 · Reply
Starlord10
Starlord10 Apr. 17 at 1:26 PM
@AboveTheHorizon you pointed out $NN, $TERN very early and I bought big positions in both. They have done very well! Thank you! Are you still in $NN for the upcoming NPRM?
1 · Reply
DragonAlgo
DragonAlgo Apr. 16 at 9:47 AM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $2.70 Stop: $1.94 TP1: $3.51 TP2: $4.59 TP3: $6.48 System-defined risk profile. 🔗 https://dragonalgo.com
0 · Reply
BioTechHealthX
BioTechHealthX Apr. 16 at 4:05 AM
$TERN Terns Pharmaceuticals is quietly targeting both obesity and oncology—two of the biggest money-making spaces in healthcare. With a growing pipeline and rising analyst attention, this under-the-radar stock could be setting up for a major breakout investors don’t want to miss. https://biotechhealthx.com/biotech-news/heres-why-you-must-keep-an-eye-to-terns-pharmaceuticals-tern/
0 · Reply
DragonAlgo
DragonAlgo Apr. 15 at 2:41 PM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $2.75 Stop: $1.98 TP1: $3.58 TP2: $4.67 TP3: $6.60 System-defined risk profile. 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Apr. 15 at 12:49 AM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $2.73 Stop: $1.96 TP1: $3.54 TP2: $4.63 TP3: $6.54 Momentum tape remains active. 🔗 https://dragonalgo.com
0 · Reply
erevnon
erevnon Apr. 14 at 6:07 PM
JP Morgan maintains Terns Pharmaceuticals $TERN at Overweight and raises the price target from $44 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
DragonAlgo
DragonAlgo Apr. 14 at 6:26 AM
🐉 $TERN PUT — DragonAlgo® Signal Contract: TERN PUT Expiry: 2026-04-17 | Strike: $39.00 | Type: PUT Option Plan (premium): Entry: $0.02 Stop: $0.01 TP1: $0.03 TP2: $0.03 TP3: $0.05 System-defined risk profile. 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Apr. 13 at 12:59 PM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $52.50 | Type: CALL Option Plan (premium): Entry: $0.30 Stop: $0.22 TP1: $0.39 TP2: $0.51 TP3: $0.72 🔗 https://dragonalgo.com
0 · Reply
BioTechHealthX
BioTechHealthX Apr. 12 at 5:56 AM
$CRDL $INO $LQDA $OCGN $TERN These top 10 microcap biotech stocks are gaining momentum with strong pipelines and upcoming catalysts. Discover the high-growth biotech companies that could deliver explosive returns in today’s market. https://biotechhealthx.com/biotech-news/top-10-microcap-biotech-stocks-that-could-multiply-your-money-fast/
1 · Reply
Latest News on TERN
Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?

Apr 15, 2026, 7:59 AM EDT - 4 days ago

Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?

SLNO WSR

Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review

Apr 7, 2026, 2:28 PM EDT - 12 days ago

Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review

MRK

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

Apr 7, 2026, 9:00 AM EDT - 12 days ago

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

MRK

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Apr 2, 2026, 4:05 PM EDT - 17 days ago

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst

Mar 25, 2026, 11:20 AM EDT - 25 days ago

Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst

MRK

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

Mar 25, 2026, 7:14 AM EDT - 25 days ago

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

MRK

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma

Mar 25, 2026, 6:51 AM EDT - 25 days ago

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma

MRK

Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns

Mar 25, 2026, 6:49 AM EDT - 25 days ago

Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns

MRK

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Mar 25, 2026, 6:48 AM EDT - 25 days ago

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

MRK

Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports

Mar 24, 2026, 9:14 PM EDT - 26 days ago

Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports

MRK

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Feb 25, 2026, 4:05 PM EST - 7 weeks ago

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 3 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 4:05 PM EST - 3 months ago

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Terns CEO Amy Burroughs talks cancer drug trial win

Dec 15, 2025, 6:31 PM EST - 4 months ago

Terns CEO Amy Burroughs talks cancer drug trial win

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 11, 2025, 4:05 PM EST - 4 months ago

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Terns Announces Pricing of Upsized $650 Million Public Offering

Dec 9, 2025, 11:30 PM EST - 4 months ago

Terns Announces Pricing of Upsized $650 Million Public Offering

Cancer Study Buoys These Small Biotechs

Dec 9, 2025, 3:31 PM EST - 4 months ago

Cancer Study Buoys These Small Biotechs

ACLX LEGN

Terns Announces Proposed Public Offering

Dec 9, 2025, 6:12 AM EST - 4 months ago

Terns Announces Proposed Public Offering

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

Dec 8, 2025, 2:45 PM EST - 4 months ago

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

Nov 14, 2025, 4:05 PM EST - 5 months ago

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 10, 2025, 4:05 PM EST - 5 months ago

Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades

Nov 3, 2025, 1:05 PM EST - 5 months ago

Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Nov 3, 2025, 9:05 AM EST - 5 months ago

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?

Oct 22, 2025, 2:43 PM EDT - 6 months ago

Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?

Terns Pharma ends obesity drug program after mid-stage trial data

Oct 21, 2025, 4:56 PM EDT - 6 months ago

Terns Pharma ends obesity drug program after mid-stage trial data

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Oct 21, 2025, 4:05 PM EDT - 6 months ago

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

Aug 21, 2025, 4:05 PM EDT - 8 months ago

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 4:05 PM EDT - 9 months ago

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Jun 23, 2025, 4:07 PM EDT - 10 months ago

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 29, 2025, 4:05 PM EDT - 11 months ago

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

May 14, 2025, 9:30 AM EDT - 1 year ago

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 8, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Feb 26, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 8:05 AM EST - 1 year ago

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Feb 24, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Feb 20, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Feb 3, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Terns's stock soars as analysts cheer leukemia data — and predict more gains

Dec 4, 2024, 1:18 PM EST - 1 year ago

Terns's stock soars as analysts cheer leukemia data — and predict more gains

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Dec 3, 2024, 8:01 AM EST - 1 year ago

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Top 3 Health Care Stocks You'll Regret Missing In Q4

Nov 19, 2024, 7:52 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

AMRN SLN

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

Nov 18, 2024, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

DragonAlgo
DragonAlgo Apr. 18 at 12:35 AM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-05-15 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $2.78 Stop: $2.00 TP1: $3.61 TP2: $4.72 TP3: $6.66 Rules-based execution profile. 🔗 https://dragonalgo.com
0 · Reply
Starlord10
Starlord10 Apr. 17 at 1:26 PM
@AboveTheHorizon you pointed out $NN, $TERN very early and I bought big positions in both. They have done very well! Thank you! Are you still in $NN for the upcoming NPRM?
1 · Reply
DragonAlgo
DragonAlgo Apr. 16 at 9:47 AM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $2.70 Stop: $1.94 TP1: $3.51 TP2: $4.59 TP3: $6.48 System-defined risk profile. 🔗 https://dragonalgo.com
0 · Reply
BioTechHealthX
BioTechHealthX Apr. 16 at 4:05 AM
$TERN Terns Pharmaceuticals is quietly targeting both obesity and oncology—two of the biggest money-making spaces in healthcare. With a growing pipeline and rising analyst attention, this under-the-radar stock could be setting up for a major breakout investors don’t want to miss. https://biotechhealthx.com/biotech-news/heres-why-you-must-keep-an-eye-to-terns-pharmaceuticals-tern/
0 · Reply
DragonAlgo
DragonAlgo Apr. 15 at 2:41 PM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $2.75 Stop: $1.98 TP1: $3.58 TP2: $4.67 TP3: $6.60 System-defined risk profile. 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Apr. 15 at 12:49 AM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $2.73 Stop: $1.96 TP1: $3.54 TP2: $4.63 TP3: $6.54 Momentum tape remains active. 🔗 https://dragonalgo.com
0 · Reply
erevnon
erevnon Apr. 14 at 6:07 PM
JP Morgan maintains Terns Pharmaceuticals $TERN at Overweight and raises the price target from $44 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
DragonAlgo
DragonAlgo Apr. 14 at 6:26 AM
🐉 $TERN PUT — DragonAlgo® Signal Contract: TERN PUT Expiry: 2026-04-17 | Strike: $39.00 | Type: PUT Option Plan (premium): Entry: $0.02 Stop: $0.01 TP1: $0.03 TP2: $0.03 TP3: $0.05 System-defined risk profile. 🔗 https://dragonalgo.com
0 · Reply
DragonAlgo
DragonAlgo Apr. 13 at 12:59 PM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $52.50 | Type: CALL Option Plan (premium): Entry: $0.30 Stop: $0.22 TP1: $0.39 TP2: $0.51 TP3: $0.72 🔗 https://dragonalgo.com
0 · Reply
BioTechHealthX
BioTechHealthX Apr. 12 at 5:56 AM
$CRDL $INO $LQDA $OCGN $TERN These top 10 microcap biotech stocks are gaining momentum with strong pipelines and upcoming catalysts. Discover the high-growth biotech companies that could deliver explosive returns in today’s market. https://biotechhealthx.com/biotech-news/top-10-microcap-biotech-stocks-that-could-multiply-your-money-fast/
1 · Reply
BioTechHealthX
BioTechHealthX Apr. 12 at 2:47 AM
$CRDL $CTMX $FENC $INO $TERN These biotech microcap stocks are flying under the radar but showing massive growth potential. Discover 10 high-risk, high-reward biotech plays that could deliver explosive returns as clinical catalysts approach. https://biotechhealthx.com/biotech-news/top-10-best-biotech-microcap-stocks-that-could-explode-10x-in-2026/
0 · Reply
DragonAlgo
DragonAlgo Apr. 11 at 12:26 AM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $2.65 Stop: $1.91 TP1: $3.45 TP2: $4.51 TP3: $6.36 🔗 https://dragonalgo.com
0 · Reply
Raumerica
Raumerica Apr. 9 at 2:51 AM
$TERN $TNYA If you like Amy, you are going to love David Goeddel, who owns 25% of the company. Punch his name into Google or AI
1 · Reply
DragonAlgo
DragonAlgo Apr. 9 at 12:09 AM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $2.75 Stop: $1.98 TP1: $3.58 TP2: $4.67 TP3: $6.60 🔗 https://dragonalgo.com
0 · Reply
ConclusionWorking
ConclusionWorking Apr. 8 at 8:03 PM
$TNYA Opened a small position here. Only because Amy Burroughs is on the Board of Directors. She's the CEO of $TERN which was just acquired by Merck. I dont know if she's actively involved here, but I bought in hoping her experience may lead to success here.
0 · Reply
ConclusionWorking
ConclusionWorking Apr. 8 at 7:57 PM
Opened a small position here. Only because Amy Burroughs is on the Board of Directors. She is the CEO at $TERN Pharmaceuticals, who was just acquired by Merck. I dont know if she's involved here or not, but she's proven in the industry and hopefully her experience leads to Tenaya's success.
0 · Reply
DragonAlgo
DragonAlgo Apr. 8 at 4:36 AM
🐉 $TERN CALL — DragonAlgo® Signal Contract: TERN CALL Expiry: 2026-04-17 | Strike: $50.00 | Type: CALL Option Plan (premium): Entry: $2.75 Stop: $1.98 TP1: $3.58 TP2: $4.67 TP3: $6.60 🔗 https://dragonalgo.com
0 · Reply
TradingAssistAI
TradingAssistAI Apr. 8 at 2:43 AM
$TERN opening right on VWAP, volume's running 6.6x avg already. RSI at 25 catching my attention this morning. Not a recommendation.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 7 at 7:46 PM
$SLS $TERN 4 Responses of 6 additional Chronic Myeloid Leukemia patients. Bought for $6.7B... SLS Current MCAP $0.79B
0 · Reply
blackalienayy
blackalienayy Apr. 7 at 7:39 PM
$TERN https://www.biopharmadive.com/news/merck-terns-bidders-acquire-deal-lower-leukemia-drug/816811/
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 7 at 7:24 PM
$SLS https://archive.ph/JGQEQ#selection-1391.0-1391.123 -- $TERN Published Chronic Myeloid Leukemia Trial data.
0 · Reply
flytrader1
flytrader1 Apr. 7 at 5:49 PM
$TERN Someone is betting on a slightly higher buyout price
0 · Reply